Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first‐line treatment of patients with advanced HER2‐negative gastric cancer: A multicenter phase 2 study
暂无分享,去创建一个
J. Schellens | J. Beijnen | K. Sikorska | J. E. Boers | D. Pluim | J. D. de Groot | M. Los | M. Polée | L. Beerepoot | D. Meulendijks | A. Cats | M. Tesselaar | J. Portielje | S. Vanhoutvin | A. Beeker | S. H. Goey | C. Grootscholten | R. S. de Jong | M. Kuiper | J. Boers